RICHLAND, WASHINGTON – April 13, 2021 – Isoray, Inc. (NYSE American: ISR), a medical technology company and seed brachytherapy innovator, today announced that Donna Fort has been appointed Vice President, Sales and Marketing. CEO Lori Woods said Fort’s appointment...
RICHLAND, WASHINGTON – March 31, 2021 – A recently published small prospective series of patients with recurrent head and neck (H&N) cancers treated with surgical resection and Isoray’s Cesium-131 brachytherapy found potential benefits that support further...
RICHLAND, WASHINGTON – March 3, 2021 – Isoray, Inc. (NYSE American: ISR), a medical technology company and seed brachytherapy innovator, today announced that Chief Executive Officer Lori Woods will present at the Oppenheimer 31st Annual Healthcare Conference on...
RICHLAND, WASHINGTON – February 16, 2021 – Isoray, Inc. (NYSE American: ISR), a medical technology company and seed brachytherapy innovator, today announced that Lisa Lauer has been appointed Vice President, Business Development. CEO Lori Woods says Lauer’s...
Revenue Increased 7% Year-Over-Year Non-Prostate Brachytherapy Revenue Increased 92% Year-Over-Year RICHLAND, WASHINGTON – February 9, 2021 – Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy powering expanding...
Conference Call is Tuesday, February 9, 2021 at 4:30 p.m. ET/1:30 p.m. PT RICHLAND, WASHINGTON – February 5, 2021– Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy powering expanding treatment options throughout the...
RICHLAND, Wash., February 4, 2021 - Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy powering expanding treatment options throughout the body, announced the pricing of its public offering of 36,000,000 shares of its...
RICHLAND, Wash., February 3, 2021 - Isoray, Inc. (NYSE AMERICAN: ISR) (“Isoray” or the “Company”), a medical technology company and innovator in seed brachytherapy powering expanding treatment options throughout the body, today announced that it intends to offer and...
RICHLAND, WASHINGTON – January 7, 2021 – Isoray, Inc. (NYSE American: ISR), a medical technology company and seed brachytherapy innovator powering expanding treatment options throughout the body, today announced that Chief Executive Officer Lori Woods will present at...
Studies Demonstrate Impact of Proprietary Isotope on Prostate and Brain Cancers At World’s Premier Radiation Oncology Society RICHLAND, WASHINGTON – November 24, 2020 – The importance of Isoray, Inc.’s (NYSE American: ISR) Cesium-131 in treating prostate and brain...
Revenue Increased 3% Year-Over-Year Non-Prostate Brachytherapy Revenue Increased 104% Year-Over-Year RICHLAND, WASHINGTON – November 10, 2020 – Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy powering expanding...
Conference Call is Tuesday, November 10, 2020 at 4:30 p.m. ET/1:30 p.m. P RICHLAND, WASHINGTON – November 2, 2020 – Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy, today announced that it will host a conference call...
RICHLAND, Wash., October 20, 2020 - Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy powering expanding treatment options throughout the body, announced the pricing of its public offering of 18,269,230 shares of its...